Peripartum cardiomyopathy

Cardiology in Review

Volumn 14, Issue 1, 2006, Pages 35-42

  Ro, Angela ^a   Frishman, William H ^b,c  

^a ST VINCENT S HOSPITAL   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cardiomyopathy in pregnancy; Heart failure; Peripartum cardiomyopathy; Pregnancy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; LEVOSIMENDAN; METOPROLOL; MILRINONE; NITRATE; NITROPRUSSIDE SODIUM; PENTOXIFYLLINE; REMIFENTANIL; VASODILATOR AGENT; VERAPAMIL; WARFARIN; CARDIOVASCULAR AGENT;

BRADYCARDIA; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL IMMUNOLOGY; CLINICAL TRIAL; CONGENITAL HEART BLOCK; CONGENITAL HYPOTHYROIDISM; EXERCISE; FETUS DISEASE; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART GRAFT; HUMAN; HYPOTENSION; MEDICAL RESEARCH; MORTALITY; NUTRITIONAL DISORDER; PREGNANCY DISORDER; PREMATURE LABOR; PREVALENCE; PROGNOSIS; REVIEW; SODIUM RESTRICTION; FEMALE; HIGH RISK PREGNANCY; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATION; PUERPERIUM; RISK FACTOR; SURVIVAL RATE;

CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; FEMALE; HUMANS; INCIDENCE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY, HIGH-RISK; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 33644876452     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000174805.68081.f7     Document Type: Review

References (51)

1. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci. 1937;19:185-199.
2. Mehta NJ, Mehta RN, Khan IA. Peripartum cardiomyopathy: clinical and therapeutic aspects. Angiology. 2001;52:759-762.
3. James PR. A review of peripartum cardiomyopathy. Int J Clin Pract. 2004;58:363-365.
4. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy. Clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050-2055.
5. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States 1991-1997. Obstet Gynecol. 2003;102:1326-1331.
6. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1052-1061.
7. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000;140:785-791.
8. Brown CS, Bertolet BD. Peripartum cardiomyopathy: a comprehensive review. Am J Obstet Gynecol. 1998;178:409-414.
9. Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81:922-928.
10. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183-1188.
11. Cénac A, Djibo A, Chaigneau C, et al. Are anti-Chlamydia pneumoniae antibodies prognosis indicators for peripartum cardiomyopathy? J Cardiovasc Risk. 2003;10:195-199.
12. Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35:701-705.
13. Sundstrom JB, Fett JD, Carraway RD, et al. Is peripartum cardiomyopathy an organ-specific autoimmune disease? Autoimmun Rev. 2002;1:73-77.
14. Ford L, Abdullahi A, Anjorin FI, et al. The outcome of peripartum cardiac failure in Zaria, Nigeria. QJM. 1998;91:93-103.
15. Fett JD, Ansari AA, Sundstrom JB, et al. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol. 2002;86:311-316.
16. Lampert MB, Hibbard J, Weinart L, et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol. 1993;168:493-495.
17. Ray P, Murphy GJ, Shutt LE. Recognition and management of maternal cardiac disease in pregnancy. Br J Anaesth. 2004;93:428-439.
18. Pierce JA. Familial occurrence of post partal heart failure. Arch Intern Med. 1963;111:163-166.
19. Massad LS, Reiss CK, Mutch DG, et al. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol. 1993;81:886-888.
20. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J. 1995;129:421-422.
21. Gemici G, Tezcan H, Fak AS, et al. Peripartum cardiomyopathy presenting with repetitive monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2004;27:557-558.
22. Palma EC, Saxenberg V, Vijayaraman P, et al. Histopathological correlation of ablation lesions guided by noncontact mapping in a patient with peripartum cardiomyopathy and ventricular tachycardia. Pacing Clin Electrophysiol. 2001;24:1812-1815.
23. Kaufman I, Bondy R, Benjamin A. Peripartum cardiomyopathy and thromboembolism; anesthetic management and clinical course of an obese, diabetic patient. Can J Anaesth. 2003;50:161-165.
24. Nishi I, Ishimitsu T, Ishizu T, et al. Peripartum cardiomyopathy and biventricular thrombi. Circ J. 2002;66:863-865.
25. Lasinska-Kowara M, Dudziak M, Suchorzewska J. Two cases of postpartum cardiomyopathy initially misdiagnosed for pulmonary embolism. Can J Anaesth. 2001;48:773-777.
26. Dickfeld T, Gagliardi JP, Marcos J, et al. Peripartum cardiomyopathy presenting as an acute myocardial infarction. Mayo Clin Proc. 2002;77:500-550.
27. Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular pharmacotherapeutic consideration during pregnancy and lactation. Cardiol Rev. 2004;12:201-221, 240-260.
28. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
29. Mohler ER, Sorensen LC, Ghali JK, et al. Role of cytokine in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. J Am Coll Cardiol. 1997;30:35-41.
30. Frishman WH. Carvedilol. N Engl J Med. 1998;229:1759-1765.
31. Ngo A, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: McGraw Hill; 1997:1309-1345.
32. Benlolo S, Lefoll C, Katchatouryan V, et al. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg. 2004;98:822-824.
33. Sonnenblick EH, LeJemtel TH, Frishman WH. Inotropic agents. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:191-202.
34. Frishman WH. Advances in positive inotropic therapy: levosimendan [Editorial]. Crit Care Med. 2003;31:2408-2409.
35. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:627S-644S.
36. Frishman WH, O'Brien M, Naseer N, et al. Innovative drug treatments for viral and autoimmune myocarditis. Heart Dis. 2002;4:171-183.
37. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
38. Sliwa K, Skudicky D, Candy G, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4:305-309.
39. Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004;109:750-755.
40. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999;34:177-180.
41. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003;108:3036-3041.
42. Velickovic IA, Leicht CH. Continuous spinal anesthesia for cesarean section in a parturient with severe recurrent peripartum cardiomyopathy. Int J Obstet Anesth. 2004;13:40-43.
43. Connelly NR, Chin MT, Parker RK, et al. Pregnancy and delivery in a patient with recent peripartum cardiomyopathy. Int J Obstet Anesth. 1998;7:38-41.
44. Pirlet M, Baird M, Pryn S, et al. Low dose combined spinal-epidural anaesthesia for caesarean section in a patient with peripartum cardiomyopathy. Int J Obstet Anesth. 2000;9:189-192.
45. Shnaider R, Ezri T, Szmuk P, et al. Combined spinal-epidural anesthesia for cesarean section in a patient with peripartum dilated cardiomyopathy. Can J Anaesth. 2001;48:681-683.
46. McCarroll CP, Paxton LD, Elliott P, et al. Use of remifentanil in a patient with peripartum cardiomyopathy requiring caesarean section. Br J Anaesth. 2001;86:135-138.
47. Lampert MB, Weinert L, Hibbard J, et al. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol. 1997;176:189-195.
48. Sutton MS, Cole P, Plappert M, et al. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J. 1991;121:1776-1778.
49. Sliwa K, Forster O, Zhanje F, et al. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol. 2004;93:1441-1443.
50. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567-1571.
51. Elkayam U. Pregnant again after peripartum cardiomyopathy: to be or not to be? Eur Heart J. 2002;23:753-756.